Glioblastoma (GBM) is an aggressive and fatal brain cancer, with a median survival of just 12-18 months despite treatment. We have developed a CAR-T cell therapy for GBM targeting the tumors directly, while secreting a CD47-blocker to reprogram macrophages. With our therapy we expect increased survival rates and significantly reduced side-effects compared to standard-of-care treatments and other new product developments (e.g. ADCs).
Preclinical POC completed (Nature Communications publication, 09Nov2024). Targeting IMPD submission and FIH clinical start within 2025.
The company will be a spin-off from University of Basel. Founders: Prof. Dr. Gregor Hutter (Neurosurgeon & Group leader Brain Tumor Immunotherapy program, University of Basel) and Christoph Engelbrecht (profile see above).